Status:
COMPLETED
Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia
Lead Sponsor:
Centre Hospitalier Universitaire Vaudois
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The results of the study "schizophrenia, related disorders and glutathione" conducted at the Laboratory of Psychiatric Neuroscience (LUNEP) DUPA of Lausanne, reinforce the hypothesis proposed that a d...
Detailed Description
The results of the study "schizophrenia, related disorders and glutathione" conducted at the Laboratory of Psychiatric Neuroscience (LUNEP) DUPA of Lausanne, reinforce the hypothesis proposed that a d...
Eligibility Criteria
Inclusion
- patients (male or female, aged 18 to 65 years, QI\>70) meeting the DSM-IV criteria (established by a senior psychiatrist) for schizophrenia and have the capacity to consent to the study. The study population include both inpatients and outpatients who are currently taking at least one of the following:Olanzapine, Clozapine, Haloperidol, Risperidone, Flupenthixol, or Fluphenazine. The following guidelines have been established for potential medication changes that patients may undergo during the course of the trial.
- dose changes to existing medication (either increases or decreases in dose) will be accepted and participants will be allowed to continue with the trial.
- A change in primary antipsychotics from one medication to another will require participants to withdrawn from the study.
- An addiction of another antipsychotic, secondary to the existing antipsychotic treatment (primary antipsychotic) will be acceptable providing that there isn't a complete change from one antipsychotic to another.
Exclusion
- pregnancy
- acute psychotic state, preventing the patient cooperation
- co-morbidity with drug dependency
- organic cerebral disease, major somatic diseases
- abnormal renal, hepatic, thyroid or hematological findings
- treatment with a regulator of mood(lithium, valproate, topiramate, lamotrigine et carbamazepine)
- allergy to NAC
- treatment with antioxidants
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01506765
Start Date
August 1 2003
End Date
September 1 2006
Last Update
January 18 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.